Malasía - enska - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

multi herbs pharmaceutical (m) sdn bhd - rhizoma ligusticum chuanxiong; rhizoma dioscorea opposita; cyperus rotundus; radix astragali seu hedysari; poria cocos (schw.) wolf.; margarita/pearls; radix angelica sinensis; radix panax ginsen; radix rehmannia glutinosa; rhizoma corydalis turtschaninovii; herba leonurus heterophyclus -

Malasía - enska - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

multi herbs pharmaceutical (m) sdn bhd - radix polygala tenuifolia; herba saururus chinensis; cordycep sinensis; radix polygonum multiflorum; fructus amomum villosum lour; rhizoma acorus gramineus -

Malasía - enska - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

multi herbs pharmaceutical (m) sdn bhd - eurycoma longifolia radix/tongkat ali -

Malasía - enska - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

multi herbs pharmaceutical (m) sdn bhd - momordica charantia l. (bitter gourd) extract -

Malasía - enska - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

multi herbs pharmaceutical (m) sdn bhd - ginkgo biloba dried leaf powder; ginkgo biloba 50:1 extract -

Ástralía - enska - APVMA (Australian Pesticides and Veterinary Medicines Authority)

kenso corporation (m) sdn. bhd. - s-metolachlor - emulsifiable concentrate - s-metolachlor anilide/aniline-acetanilides active 960.0 g/l - herbicide - barley | broccoli | brussels sprouts | cabbage | canola | cauliflower | cocksfoot | cotton | green bean | haifa white clover | m - annual or wimmera ryegrass | annual ryegrass - suppression | apple-of-peru | awnless barnyard grass | barnyard grass or water grass | barnyard or water grass | bellvine | billygoat weed or blue top | blackberry nightshade | caltrop or yellow vine | chickweed | common cotula or carrot weed | common thornapple | crowsfoot grass | deadnettle | evening primrose | fat hen | fiddle dock | fierce thornapple | giant or black pigweed | green summer grass | guinea grass | italian ryegrass | liverseed or urochloa grass | lovegrass | mintweed | needle burr | nettle leaf goosefoot | nightshade - solanum gigrum | nightshade - solanum sarrachoides | noogoora burr | passionfruit vine | pigeon grass | pigweed spp. | potato or yellow weed | powell's amaranth or powell's slim | redroot or redroot amaranth | redshank or slim amaranth - seedling | redshank,slim or spleen amaranth | shepherd's purse | sow or milk thistle | square weed or borreria | star of bethlehem or cupid's flower | stinging or dwarf nettle | summer grass | sum

Malasía - enska - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

herbs pharma sdn bhd - polygonum multiflorum; semen cuscutae; semen allii tuberosi; radix astragali; herba epimedii; extract poria; cornu cervi extract/antler extract; corni coraceae fructus; cistanches herba; cacumen platycladi cupressaceae -

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - digoxin, quantity: 0.0625 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; maize starch; magnesium stearate; povidone; indigo carmine; oxidised maize starch; rice starch - indications as at 26 july 2000 : congestive heart failure - lanoxin is useful regardless of whether the failure is predominantly of the left or right ventricle, or involves both sides of the heart. it is particularly useful in heart failure resulting from chronic overload (hypertension, valvular lesions, atherosclerotic heart disease) in which the supply of energy is not impaired. lanoxin does not cause major benefit in situations in which the metabolic energy supply is compromised as in thyrotoxicosis, hypoxia, and severe thiamine deficiency. atrial fibrillation - because lanoxin depresses conduction in the atrioventricular bundle, producing a slower ventricular beat, it is valuable in atrial fibrillation. it will frequently convert atrial flutter into fibrillation and, upon withdrawal of the drug, normal sinus rhythm may be restored. paroxysmal atrial tachycardia - lanoxin may relieve or prevent an attack, but its use in paroxysmal ventricular tachycardia is dangerous.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - digoxin, quantity: 0.25 mg/ml - injection, solution - excipient ingredients: citric acid monohydrate; dibasic sodium phosphate; propylene glycol; water for injections; ethanol - indications as at 26 july 2000 : congestive heart failure - lanoxin is useful regardless of whether the failure is predominantly of the left or right ventricle, or involves both sides of the heart. it is particularly useful in heart failure resulting from chronic overload (hypertension, valvular lesions, atherosclerotic heart disease) in which the supply of energy is not impaired. lanoxin does not cause major benefit in situations in which the metabolic energy supply is compromised as in thyrotoxicosis, hypoxia, and severe thiamine deficiency. atrial fibrillation - because lanoxin depresses conduction in the atrioventricular bundle, producing a slower ventricular beat, it is valuable in atrial fibrillation. it will frequently convert atrial flutter into fibrillation and, upon withdrawal of the drug, normal sinus rhythm may be restored. paroxysmal atrial tachycardia - lanoxin may relieve or prevent an attack, but its use in paroxysmal ventricular tachycardia is dangerous.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - digoxin, quantity: 25 microgram/ml - injection, solution - excipient ingredients: ethanol; propylene glycol; citric acid; dibasic sodium phosphate; water for injections - indications as at 26 july 2000 : congestive heart failure - lanoxin is useful regardless of whether the failure is predominantly of the left or right ventricle, or involves both sides of the heart. it is particularly useful in heart failure resulting from chronic overload (hypertension, valvular lesions, atherosclerotic heart disease) in which the supply of energy is not impaired. lanoxin does not cause major benefit in situations in which the metabolic energy supply is compromised as in thyrotoxicosis, hypoxia, and severe thiamine deficiency. atrial fibrillation - because lanoxin depresses conduction in the atrioventricular bundle, producing a slower ventricular beat, it is valuable in atrial fibrillation. it will frequently convert atrial flutter into fibrillation and, upon withdrawal of the drug, normal sinus rhythm may be restored. paroxysmal atrial tachycardia - lanoxin may relieve or prevent an attack, but its use in paroxysmal ventricular tachycardia is dangerous.